Maintenance of response in patients with moderate-to-severe plaque psoriasis treated with mirikizumab and retreatment response after loss of efficacy - 22/08/19
Kristian Reich, Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany; Kim A. Papp, K. Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, Canada; Craig Leonardi, Saint Louis University School of Medicine, Saint Louis; Alan Menter, Menter Cosmetic Institute, Dallas; Joanne Li, Eli Lilly and Company, Indianapolis; Jay Tuttle, Eli Lilly and Company, Indianapolis; Dipak Patel, Eli Lilly and Company, Indianapolis; Vipin Arora, Eli Lilly and Company, Indianapolis; Stuart Friedrich, Eli Lilly and Company, Indianapolis; Robert Bissonnette, Innovaderm Research, Montreal, Canada
Le texte complet de cet article est disponible en PDF.| Supported by Eli Lilly and Company. |
Vol 81 - N° 4S1
P. AB236 - octobre 2019 Retour au numéro
Article précédent
- Lymph node ratio is an independent prognostic factor in pathologic node-positive cases of Merkel cell carcinoma treated with lymph node dissection
- Maintenance of response through up to 3-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?